Armune BioScience nets $5 mln Series A
Armune BioScience, a developer of a blood test that assesses the risk of prostate cancer, has secured $5 million in Series A funding. The investors included Grand Angels.
7 September 2016•1 min read
Armune BioScience, a developer of a blood test that assesses the risk of prostate cancer, has secured $5 million in Series A funding. The investors included Grand Angels.
